| On multi-armed bandit designs for dose-finding trials M Aziz, E Kaufmann, MK Riviere Journal of Machine Learning Research 22 (14), 1-38, 2021 | 67* | 2021 |
| A Bayesian dose‐finding design for drug combination clinical trials based on the logistic model MK Riviere, Y Yuan, F Dubois, S Zohar Pharmaceutical statistics 13 (4), 247-257, 2014 | 65 | 2014 |
| Designs of drug-combination phase I trials in oncology: a systematic review of the literature MK Riviere, C Le Tourneau, X Paoletti, F Dubois, S Zohar Annals of Oncology 26 (4), 669-674, 2015 | 61 | 2015 |
| Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization MK Riviere, Y Yuan, JH Jourdan, F Dubois, S Zohar Statistical methods in medical research 27 (2), 466-479, 2018 | 54 | 2018 |
| Competing designs for drug combination in phase I dose‐finding clinical trials MK Riviere, F Dubois, S Zohar Statistics in medicine 34 (1), 1-12, 2015 | 47 | 2015 |
| A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent MK Riviere, Y Yuan, F Dubois, S Zohar Journal of the Royal Statistical Society: Series C (Applied Statistics) 64 …, 2015 | 45 | 2015 |
| An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect models MK Riviere, S Ueckert, F Mentré Biostatistics 17 (4), 737-750, 2016 | 22 | 2016 |
| Bayesian methods for the analysis of early‐phase oncology basket trials with information borrowing across cancer types J Jin, MK Riviere, X Luo, Y Dong Statistics in Medicine 39 (25), 3459-3475, 2020 | 18 | 2020 |
| Cephalometric assessment of craniofacial dysmorphologies in relation with Msx2 mutations in mouse Y Simon, A Marchadier, MK Riviere, K Vandamme, F Koenig, F Lezot, ... Orthod Craniofac Res. 17 (2), 92-105, 2014 | 17 | 2014 |
| Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics E Gerard, S Zohar, HT Thai, C Lorenzato, MK Riviere, M Ursino Biometrics 78 (1), 300-312, 2022 | 10 | 2022 |
| Robust designs in longitudinal studies accounting for parameter and model uncertainties–application to count data F Loingeville, TT Nguyen, MK Riviere, F Mentré Journal of biopharmaceutical statistics 30 (1), 31-45, 2020 | 8* | 2020 |
| Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens E Gerard, S Zohar, C Lorenzato, M Ursino, M Riviere Statistics in Medicine 40 (23), 5096-5114, 2021 | 5 | 2021 |
| dfcomb: An R-package for phase I/II trials of drug combinations MK Riviere, JH Jourdan, S Zohar Computer methods and programs in biomedicine 125, 117-133, 2016 | 2 | 2016 |
| Improved Confidence Intervals and P-Values by Sampling from the Normalized Likelihood S Ueckert, MK Riviere, F Mentre JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 42, S56-S57, 2015 | 2 | 2015 |
| Response to comments on ‘Competing designs for drug combination in phase I dose‐finding clinical trials’ by G. Yin, R. Lin and N. Wages MK Riviere, F Dubois, S Zohar Statistics in medicine 34 (1), 23-26, 2015 | 1 | 2015 |
| Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics E Gerard, S Zohar, HT Thai, C Lorenzato, MK Riviere, M Ursino Biometrics 78 (1), 300-312, 2022 | | 2022 |
| Modélisation bayésienne d’une toxicité bivariée en essais de phase précoce en oncologie évaluant des régimes de dose E Gérard, S Zoha, M Ursino, M Rivière Revue d'Épidémiologie et de Santé Publique 69, S13-S14, 2021 | | 2021 |
| Comments on ‘A comparative study of adaptive dose‐finding designs for phase I oncology trials of combination therapies’ MK Riviere, S Zohar Statistics in Medicine 35 (3), 475-478, 2016 | | 2016 |
| Designs adaptifs de recherche de dose en oncologie dans le cadre de combinaisons de molécules et de molécules ciblées MK Rivière Paris 7, 2014 | | 2014 |
| Bandit Algorithms for Early-Stage Clinical Trials E Kaufmann, M Aziz, MK Riviere | | |
Sarah ZoharINSERMBestätigte E-Mail-Adresse bei inserm.fr
